Romidepsin in the treatment of cutaneous T-cell lymphoma

References

• CriscioneVDWeinstockMAIncidence of cutaneous T-cell lymphoma in the United States, 1973–2002Arch Dermatol200714385485917638728
   PubMed Web of Science ®Google Scholar
• BunnPALambergSIReport of the Committee on Staging and Classification of Cutaneous T-cell LymphomasCancer Treat Rep197963725728445521
   PubMedGoogle Scholar
• VonderheidECBernengoMGThe Sezary Syndrome: hematologic criteriaHematol Oncol Clin North Am2003171367138914710890
   PubMed Web of Science ®Google Scholar
• ZackheimHSAminSKashani-SabetMPrognosis in cutaneous T-cell lymphoma by skin stage: long term survival in 489 patientsJ Am Acad Dermatol19994041842510071312
   PubMed Web of Science ®Google Scholar
• UedaHNakajimaHHoriYFR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968, I: Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activityJ Antibiot (Tokyo)1994473013107513682
   PubMed Web of Science ®Google Scholar
• UedaHMandaTMatsumotoSFR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968, III: Antitumor activities on experimental tumors in miceJ Antibiot (Tokyo)1994473153238175484
   PubMed Web of Science ®Google Scholar
• NakajimaHKimYBTeranoHFR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitorExp Cell Res19982411261339633520
   PubMed Web of Science ®Google Scholar
• FurumaiRAkihisaMNobuyukiKFK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylasesCancer Res200262491612208741
   PubMed Web of Science ®Google Scholar
• BhallaKNEpigenetic and chromatin modifiers as targeted therapy of hematologic malignanciesJ Clin Oncol2005233971399315897549
   PubMed Web of Science ®Google Scholar
• PiekarzRBatesSEpigenetic modifiers: basic understanding and clinical developmentClin Cancer Res200915123918392619509169
   PubMed Web of Science ®Google Scholar
• LeighEYanPGordonKSHistone deacetylase inhibitor panobinostat induced clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphomaClin Cancer2008144500
   Web of Science ®Google Scholar
• ByrdJCShinnCRaviRDepsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cellsBlood1999941401140810438728
   PubMed Web of Science ®Google Scholar
• PiekarzRLRobeyRWZhanZT-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistanceBlood20041034636464314996704
   PubMed Web of Science ®Google Scholar
• KhanSBMaududiTBartonKAnalysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myelomaBr J Haematol200412515616115059137
   PubMed Web of Science ®Google Scholar
• XiaoJAmyFPeterSEfflux of depsipeptide FK 228 (FR 901228, NSC-630176) is mediated by P-glycoprotein and multi drug resistantce-associated protein-1J Pharmacol Exp Ther20053326827615634944
   PubMed Web of Science ®Google Scholar
• RobeyRWZhanZPiekarzRLIncreased MDRI expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)Clin Cancer Res2006121547155516533780
   PubMed Web of Science ®Google Scholar
• BergSLStoneJXiaoJJPlasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primatesCancer Chemother Pharmacol200454858815042312
   PubMed Web of Science ®Google Scholar
• PeartMJTaintonKMRuefliAANovel mechanisms of apoptosis induced by histone deacetylase inhibitorsClin Cancer Res2003634460
   Google Scholar
• NewboldALindermannRKCluseLACharacterization of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsinMol Cancer Ther200871066107918483296
   PubMed Web of Science ®Google Scholar
• PageJGRodmanLEHeathJEEffect of infusion rate on toxicity of depsipeptide (NSC-630176)Proc Amer Assoc Cancer Res199536368
   Google Scholar
• LiZChanKKA subnanogram API LC/MS/MS quantitation method for depsipeptide FR901228 and its preclinical pharmacokineticsJ Pharm Biomed Anal200022334410727121
   PubMed Web of Science ®Google Scholar
• SandorVBakkeSRobeyRPhase I clinical trial of histone deacetylase inhibitor, depsipeptide (FR 901228, NSC 630176) in patients with refractory neoplasmsClin Cancer Res2002871811895901
   PubMed Web of Science ®Google Scholar
• MarshallJRizviNKauhJA phase I trial of depsipeptide (FR901228) in patients with advanced cancerJ Exp Ther Oncol2002232533212440223
   PubMedGoogle Scholar
• SukyungWErinRGXiaohongCPopulation pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphomaClin Cancer Res2009151496150319228751
   PubMed Web of Science ®Google Scholar
• ShiragaTTozukaZIshimuraRIdentification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomesBiol Pharm Bull20052812412915635176
   PubMed Web of Science ®Google Scholar
• FehrenbachTCuiYFaulstichHCharacterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteinsNauryn Schmiedebergs Archives Pharmacol2003368415420
   PubMed Web of Science ®Google Scholar
• FouladiMFurmanWChinTPhase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children’s Oncology Group reportJ Clin Oncol2006243678368516877737
   PubMed Web of Science ®Google Scholar
• ByrdJCMarcuciGParthunMRA phase I and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemiaBlood200510595996715466934
   PubMed Web of Science ®Google Scholar
• SusanEBZhirongZKennethSLaboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphomaBr J Haematol200914825626719874311
   PubMed Web of Science ®Google Scholar
• PiekarzRLRobeyRSandorVInhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case reportBlood2001982865286811675364
   PubMed Web of Science ®Google Scholar
• PiekarzRFryeRTurnerMPhase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaJ Clin Oncol2009275410541719826128
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhuerEANew guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst20009220521610655437
   PubMed Web of Science ®Google Scholar
• ChesonBDHorningSJCoiffierBReport of an international work shop to standardize response criteria for non-Hodgkin’s lymphomas: NCI Sponsored International Working GroupJ Clin Oncol199917124410561185
   PubMed Web of Science ®Google Scholar
• StevensSRKeMSParryEJQuantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the Severity-Weighted Assessment Tool (SWAT)Arch Dermatol2002138424811790166
   PubMed Web of Science ®Google Scholar
• HealdPClinical trials and efficacy assessment in the therapy of cutaneous T-cell lymphomaAnn N Y Acad Sci200194115516511594569
   PubMed Web of Science ®Google Scholar
• WhittakerSDemierreMFKimEJFinal results from a multi-center, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphomaJ Clin Oncol201028294485449120697094
   PubMed Web of Science ®Google Scholar
• OlsenEDuvicMFankelAPivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphomaJ Clin Oncol20011937638811208829
   PubMed Web of Science ®Google Scholar
• EdelsonRBergerCGasparroFTreatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary resultsN Engl J Med19873162973033543674
   PubMed Web of Science ®Google Scholar
• PiekarzRFryeRWrightJCardiac studies in patients with depsipeptide, FK28, in a phase II trial for T-cell lymphomaClin Cancer Res2006123762377316778104
   PubMed Web of Science ®Google Scholar
• RitchieDPiekarzRBlomberyPReactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series reportHaematologica2009941618162219608677
   PubMed Web of Science ®Google Scholar
• MaslakPChanelSCamachoLHPilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndromeLeukemia20062021221716357841
   PubMed Web of Science ®Google Scholar
• BlumWKlisovicRBHackansonBPhase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemiaJ Clin Oncol2007253884389117679729
   PubMed Web of Science ®Google Scholar
• SorianoAOYanhHFaderlSSafety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndromeBlood20071102302230817596541
   PubMed Web of Science ®Google Scholar
• BerensonJRYellinOMapesPA phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory diseaseJ Clin Oncol200927e19508
   Web of Science ®Google Scholar
• JFantinVRLobodaAPaweletzCPConstitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphomaCancer Res2008683785379418483262
   PubMed Web of Science ®Google Scholar
• OlsenEAKimYHKuzelTMPhase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphomaJ Clin Oncol2007253109311517577020
   PubMed Web of Science ®Google Scholar
• DuvicMBeckerJCDalleSPhase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL)Blood20081121005101118477770
   PubMed Web of Science ®Google Scholar
• FossFAdvaniRHymesKActivity of belinostat in patients with recurrent or refractory peripheral or cutaneous T-cell lymphomaHaematol Meet Rep2009313940
   Google Scholar
• ParkerCMolifeRKaravasilisVRomidepsin (FK228), a histone deacetylase inhibitor: Final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC)J Clin Oncol, ASCO Annual Meeting Proceedings2007518S15507
   Google Scholar
• StadlerWMMargolinKFerberSA phase II study of depsipeptide in refractory metastatic renal cell cancerClin Genitourin Cancer200651576016859580
   PubMed Web of Science ®Google Scholar
• WhiteheadRPRankinCHoffPMPhase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)Invest New Drugs200927546947518941712
   PubMed Web of Science ®Google Scholar
• NiesvizkyRElySMarkTPhase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myelomaCancer2011117233634220862746
   PubMed Web of Science ®Google Scholar